Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Investing Activities (2020 - 2024)

Gain Therapeutics (GANX) has 5 years of Cash from Investing Activities data on record, last reported at -$43447.0 in Q4 2024.

  • For Q4 2024, Cash from Investing Activities fell 101.38% year-over-year to -$43447.0; the TTM value through Dec 2024 reached $5.0 million, down 51.31%, while the annual FY2024 figure was $5.0 million, 51.31% down from the prior year.
  • Cash from Investing Activities reached -$43447.0 in Q4 2024 per GANX's latest filing, down from -$1.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $3.1 million in Q4 2023 and bottomed at -$14.9 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is $15516.2, with a median of -$3156.5 recorded in 2020.
  • Peak YoY movement for Cash from Investing Activities: tumbled 66066.32% in 2022, then skyrocketed 27026.26% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$14551.0 in 2020, then rose by 23.73% to -$11098.0 in 2021, then skyrocketed by 1305.89% to $133830.0 in 2022, then skyrocketed by 2247.65% to $3.1 million in 2023, then crashed by 101.38% to -$43447.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$43447.0 in Q4 2024, -$1.0 in Q3 2024, and $2.0 million in Q2 2024.